Li MY, Liu HY, Wu DT, et al
During GLP-1associated weight loss, lean-mass changes are typically adaptive and preventable , not degenerative. GLP-1 Body Composition Changes: What Clinical Trials Show About Muscle Loss Clinical trials and body-composition sub-studies of semaglutide and tirzepatide consistently demonstrate: Fat mass accounts for most weight lost during treatment. Lean mass may decrease , particularly without resistance training or adequate protein intake. In many patients, the proportion of lean mass relative to total body weight is preserved or improved , because fat loss exceeds lean loss. Key clinical insight: GLP-1/GIP therapies improve overall body composition by preferentially reducing fat massnot by causing muscle breakdown. Lean mass refers to all the non-fat tissues in the bodyprimarily skeletal muscle , but also organs, bones, connective tissue, and body waterthat support metabolism, movement, and overall physical function
Immunity 30 , 899911 (2009)
Includes: (C917) CBC without differential (C901) CMP (C157) TSH (C145) Hemoglobin AIC (C906) Lipid Panel In 4 RCTs, patients (baseline weight 96 to 105 kg) were treated for weight loss with GLP1/GIP medication weekly and lifestyle interventions (counseling, diet, and physical activity)
An analysis of 28,165 GLP-1 RA orders detected a dispensing error rate of just 0.35%
